TY - JOUR
T1 - “Mild” hyperphenylalaninemia? A case series of seven treated patients following newborn screening
AU - Viall, Sarah
AU - Ayyub, Omar
AU - Rasberry, Matthew
AU - Lyons, Kelly
AU - Ah Mew, Nicholas
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/12
Y1 - 2017/12
N2 - Hyperphenylalaninemia (HPA) is a disorder diagnosed only incidentally by newborn screening, a by-product of screening for classic phenylketonuria (PKU) which, if untreated, causes irreversible neurologic sequelae. In contrast, HPA is thought to have a benign phenotype because phenylalanine (Phe) levels are insufficiently elevated to cause neurological damage, obviating the need for rigorous dietary protein restriction. Phenylalanine below 360 μmol/L is generally considered safe, thus this threshold is both the upper therapeutic range for treated PKU and the highest Phe expected to be possible for most individuals with HPA. However, the published literature and even expert consensus provides limited guidance on long-term follow-up of Phe after this diagnosis. In particular, how frequently and vigilantly to monitor levels to evaluate for subsequent elevations above the ‘safe’ range. Upon retrospective review we identified 22 patients with HPA, ascertained via newborn screen and currently aged two to thirty-six years. All patients had an initial untreated Phe between 90 μmol/L (our upper limit of normal) and 360 μmol/L. Of these patients, seven subsequently demonstrated either fluctuating or sustained increases in Phe above 360 μmol/L. Five have been treated successfully with sapropterin therapy without dietary intervention and two have been treated with mild to moderate protein restriction. Our experience demonstrates successful treatment of these children without the traditional highly restrictive PKU diet. However, a better understanding of this disorder is necessary to more safely and appropriately identify, monitor and manage children with HPA. Synopsis One clinics’ experience with diagnostic differences in a population of Hyperphenylalaninemia patients that required treatment.
AB - Hyperphenylalaninemia (HPA) is a disorder diagnosed only incidentally by newborn screening, a by-product of screening for classic phenylketonuria (PKU) which, if untreated, causes irreversible neurologic sequelae. In contrast, HPA is thought to have a benign phenotype because phenylalanine (Phe) levels are insufficiently elevated to cause neurological damage, obviating the need for rigorous dietary protein restriction. Phenylalanine below 360 μmol/L is generally considered safe, thus this threshold is both the upper therapeutic range for treated PKU and the highest Phe expected to be possible for most individuals with HPA. However, the published literature and even expert consensus provides limited guidance on long-term follow-up of Phe after this diagnosis. In particular, how frequently and vigilantly to monitor levels to evaluate for subsequent elevations above the ‘safe’ range. Upon retrospective review we identified 22 patients with HPA, ascertained via newborn screen and currently aged two to thirty-six years. All patients had an initial untreated Phe between 90 μmol/L (our upper limit of normal) and 360 μmol/L. Of these patients, seven subsequently demonstrated either fluctuating or sustained increases in Phe above 360 μmol/L. Five have been treated successfully with sapropterin therapy without dietary intervention and two have been treated with mild to moderate protein restriction. Our experience demonstrates successful treatment of these children without the traditional highly restrictive PKU diet. However, a better understanding of this disorder is necessary to more safely and appropriately identify, monitor and manage children with HPA. Synopsis One clinics’ experience with diagnostic differences in a population of Hyperphenylalaninemia patients that required treatment.
UR - http://www.scopus.com/inward/record.url?scp=85033457989&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85033457989&partnerID=8YFLogxK
U2 - 10.1016/j.ymgme.2017.10.010
DO - 10.1016/j.ymgme.2017.10.010
M3 - Article
C2 - 29102225
AN - SCOPUS:85033457989
SN - 1096-7192
VL - 122
SP - 153
EP - 155
JO - Molecular Genetics and Metabolism
JF - Molecular Genetics and Metabolism
IS - 4
ER -